The results showed that inhibiting HDAC5 significantly increased CD8+ T cell infiltration in the tumor microenvironment, reduced the proportion of Tregs, and exhibited synergistic effects with anti-PD-1 antibodies, jointly inhibiting tumor growth (69). The gene discussed is HDAC5; the disease is neoplasm.